Characteristics | Met11/Met11, n = 80 | Met11/Thr11, n = 96 | Thr11/Thr11, n = 32 | p |
---|---|---|---|---|
Male sex | 5 (6) | 7 (7) | 1 (3) | 0.837 |
Age, mean ± SD | 54.56 ± 13.62 | 56.76 ± 13.99 | 60.28 ± 11.52 | 0.126 |
Dry mouth | 79 (99) | 93 (97) | 32 (100) | 0.46 |
Dry eyes | 79 (99) | 92 (96) | 31 (97) | 0.51 |
Altered ocular tests | 70 (87) | 89 (93) | 32 (100) | 0.47 |
Parotid scintigraphy grade III/IV | 32/70 (46) | 41/85 (48) | 15/25 (60) | 0.23 |
Positive salivary gland biopsy | 27/39 (69) | 33/47 (70) | 12/14 (86) | 0.46 |
Parotid enlargement | 20 (25) | 22 (23) | 11 (34) | 0.43 |
Fever | 6 (8) | 14 (15) | 2 (6) | 0.216 |
Arthralgia | 49 (61) | 50 (52) | 21 (65) | 0.29 |
Arthritis | 8 (10) | 12 (13) | 8 (25) | 0.22 |
Raynaud phenomenon | 15 (18) | 26 (27) | 4 (13) | 0.16 |
Vasculitis | 5 (6) | 10 (10) | 0 (0) | 0.13 |
Bronchiectasis | 8 (10) | 15 (16) | 7 (22) | 0.244 |
Pulmonary interstitial disease | 6 (8) | 8 (8) | 5 (16) | 0.374 |
Autoimmune liver disease | 5 (6) | 11 (11) | 5 (16) | 0.28 |
Renal involvement | 3 (4) | 1 (1) | 4 (13) | 0.014 |
Peripheral neuropathy | 4 (5) | 12 (13) | 2 (6) | 0.18 |
CNS involvement | 5 (6) | 11 (11) | 3 (9) | 0.49 |
ESR, mean ± SD | 39.24 ± 30.53 | 35.77 ± 32.27 | 37.47 ± 29.54 | 0.504 |
Anemia, Hb < 10 g/l | 13 (16) | 15 (16) | 4 (13) | 0.880 |
Leukopenia, < 4 × 109/l | 16 (20) | 25 (26) | 5 (16) | 0.397 |
Thrombocytopenia, < 100 × 109/l | 2 (2) | 9 (9) | 1 (3) | 0.118 |
ANA+ | 64 (80) | 86 (90) | 28 (88) | 0.186 |
RF+ | 35/79 (44) | 36 (38) | 13 (41) | 0.660 |
Anti-Ro/SS-A+ | 28 (35) | 30 (31) | 12 (38) | 0.769 |
Anti-La/SS-B+ | 24 (30) | 20 (21) | 12 (38) | 0.134 |
pSS: primary Sjögren syndrome; SP-D: surfactant protein-D; CNS: central nervous system; ESR: erythrocyte sedimentation rate; ANA: antinuclear antibody; RF: rheumatoid factor.